Drug intelligence / Profile preview

DYV800

Development stage: Preclinical
Lead developer: Dyve Biosciences
Modality: Small Molecules
Administration: Topical, Transdermal

Overview

DYV800 is a preclinical-stage topical transdermal buffering agent developed by Dyve Biosciences in collaboration with the H. Lee Moffitt Cancer Center & Research Institute. It is a patented cream formulation containing 33% sodium bicarbonate, designed to neutralize the acidic tumor microenvironment (TME) of solid tumors. By increasing the extracellular pH (pHe) of the tumor, DYV800 aims to restore immune cell migration and activation, potentially enhancing the efficacy of concurrent cancer treatments such as immunotherapies. The drug utilizes Dyve's proprietary transdermal delivery platform to overcome the compliance and efficacy limitations associated with oral buffering agents.

Other names: sodium bicarbonate transdermal cream

Beyond the preview

Go deeper on DYV800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DYV800.

Explore the full profile